BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 23291141)

  • 21. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.
    Zhao T; Chen H; Zhang T
    Med Oncol; 2012 Dec; 29(5):3017-23. PubMed ID: 22476809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer.
    Iwasaki K; Osaka Y; Tachibana S; Suda T; Ota Y; Hoshino S; Tsuchida A
    Anticancer Res; 2016 Mar; 36(3):987-94. PubMed ID: 26976988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
    Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
    Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
    Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
    Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer. A phase II study.
    Eisterer W; DE Vries A; Kendler D; Spechtenhauser B; Königsrainer A; Nehoda H; Virgolini I; Lukas P; Bechter O; Wöll E; Ofner D
    Anticancer Res; 2011 Dec; 31(12):4407-12. PubMed ID: 22199307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
    Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Ishiyama H; Hayakawa K
    Radiother Oncol; 2008 Jun; 87(3):398-404. PubMed ID: 18405987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
    Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
    Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
    Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer.
    Emi M; Hihara J; Hamai Y; Aoki Y; Okada M; Kenjo M; Murakami Y
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1499-505. PubMed ID: 22382882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma.
    Hara H; Tahara M; Daiko H; Kato K; Igaki H; Kadowaki S; Tanaka Y; Hamamoto Y; Matsushita H; Nagase M; Hosoya Y
    Cancer Sci; 2013 Nov; 104(11):1455-60. PubMed ID: 23991649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
    Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
    Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study.
    Hihara J; Hamai Y; Emi M; Murakami Y; Kenjo M; Nagata Y; Okada M
    Dis Esophagus; 2016 Nov; 29(8):1115-1120. PubMed ID: 26471962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).
    Goto H; Oshikiri T; Kato T; Nagatani Y; Funakoshi Y; Koterazawa Y; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Minami H; Kakeji Y
    PLoS One; 2024; 19(4):e0299742. PubMed ID: 38635652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
    Makino T; Yamasaki M; Miyazaki Y; Wada N; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29190316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
    Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
    Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.